These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37277843)

  • 61. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers.
    Findlow J; Bai X; Findlow H; Newton E; Kaczmarski E; Miller E; Borrow R
    Vaccine; 2015 Jun; 33(29):3322-30. PubMed ID: 26025807
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Meningococcal disease epidemiology in Brazil (2005-2018) and impact of MenC vaccination.
    Aparecido Nunes A; De Jesus Lopes De Abreu A; Cintra O; A C T Cintra M; Barbosa Coelho E; Nogueira Castro De Barros E
    Vaccine; 2021 Jan; 39(3):605-616. PubMed ID: 33358262
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A comparison of national vaccination policies to prevent serogroup B meningococcal disease.
    Sulis G; Horn M; Borrow R; Basta NE
    Vaccine; 2022 Jun; 40(26):3647-3654. PubMed ID: 35581099
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study.
    Bryan P; Seabroke S; Wong J; Donegan K; Webb E; Goldsmith C; Vipond C; Feavers I
    Lancet Child Adolesc Health; 2018 Jun; 2(6):395-403. PubMed ID: 30169281
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Subacute cerebellar ataxia following respiratory symptoms of COVID-19: a case report.
    Werner J; Reichen I; Huber M; Abela IA; Weller M; Jelcic I
    BMC Infect Dis; 2021 Mar; 21(1):298. PubMed ID: 33761897
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Acute cerebellitis in paediatric patients: Our experience.
    García-Iñiguez JP; López-Pisón FJ; Madurga Revilla P; Montejo Gañán I; Domínguez Cajal M; Monge Galindo L; Sánchez Marco SB; García Jiménez MC
    Neurologia (Engl Ed); 2019 Jun; 34(5):291-299. PubMed ID: 28318729
    [TBL] [Abstract][Full Text] [Related]  

  • 67. MenB-FHbp Meningococcal Group B Vaccine (Trumenba
    Shirley M; Taha MK
    Drugs; 2018 Feb; 78(2):257-268. PubMed ID: 29380290
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety and tolerability of Meningococcus B vaccine in patients with chronical medical conditions (CMC).
    Nicolosi L; Rizzo C; Gattinara GC; Mirante N; Bellelli E; Bianchini C; Pansini V; Villani A
    Ital J Pediatr; 2019 Oct; 45(1):133. PubMed ID: 31666107
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.
    Hellenbrand W; Koch J; Harder T; Bogdan C; Heininger U; Tenenbaum T; Terhardt M; Vogel U; Wichmann O; von Kries R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1314-43. PubMed ID: 26487381
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Meningococcal serogroup B vaccination series initiation in the United States: A real-world claims data analysis.
    Packnett ER; Zimmerman NM; Novy P; Morgan LC; Chime N; Ghaswalla P
    Hum Vaccin Immunother; 2023 Dec; 19(1):2165382. PubMed ID: 36715008
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Acute cerebellar ataxia: differential diagnosis and clinical approach.
    Pedroso JL; Vale TC; Braga-Neto P; Dutra LA; França MC; Teive HAG; Barsottini OGP
    Arq Neuropsiquiatr; 2019 Mar; 77(3):184-193. PubMed ID: 30970132
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Outcomes from the Use of Targeted Interventions to Increase Meningococcal Vaccination Rates in a Pediatric Clinic.
    Podraza L; Vasudevan J; Hudson C; Jayan A; Varman M
    J Community Health; 2022 Feb; 47(1):87-93. PubMed ID: 34389892
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lessons from mass vaccination response to meningococcal B outbreaks at US universities.
    Alderfer J; Isturiz RE; Srivastava A
    Postgrad Med; 2020 Sep; 132(7):614-623. PubMed ID: 32476532
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England.
    Ladhani SN; Andrews N; Parikh SR; Campbell H; White J; Edelstein M; Bai X; Lucidarme J; Borrow R; Ramsay ME
    N Engl J Med; 2020 Jan; 382(4):309-317. PubMed ID: 31971676
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Parental awareness of Meningococcal B vaccines and willingness to vaccinate their teens.
    Basta NE; Becker AB; Li Q; Nederhoff D
    Vaccine; 2019 Jan; 37(4):670-676. PubMed ID: 30587431
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.
    Nolan TM; Nissen MD; Naz A; Shepard J; Bedell L; Hohenboken M; Odrljin T; Dull PM
    Hum Vaccin Immunother; 2014; 10(2):280-9. PubMed ID: 24220326
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease.
    Watson PS; Turner DP
    Vaccine; 2016 Feb; 34(7):875-80. PubMed ID: 26686570
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial.
    Tapia MD; Sow SO; Tamboura B; Tégueté I; Pasetti MF; Kodio M; Onwuchekwa U; Tennant SM; Blackwelder WC; Coulibaly F; Traoré A; Keita AM; Haidara FC; Diallo F; Doumbia M; Sanogo D; DeMatt E; Schluterman NH; Buchwald A; Kotloff KL; Chen WH; Orenstein EW; Orenstein LAV; Villanueva J; Bresee J; Treanor J; Levine MM
    Lancet Infect Dis; 2016 Sep; 16(9):1026-1035. PubMed ID: 27261067
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016.
    Mentzer D; Oberle D; Keller-Stanislawski B
    Euro Surveill; 2018 Apr; 23(17):. PubMed ID: 29717697
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cerebrospinal Fluid Pleocytosis following Meningococcal B vaccination in an Infant.
    Oligbu G
    Epidemiol Mikrobiol Imunol; 2018; 67(4):191-192. PubMed ID: 30630323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.